Skip to content

Efficacy and Safety of SGLT2 Inhibitors in Different Phenotypes of Heart Failure

Efficacy and Safety of SGLT2 Inhibitors in Different Phenotypes of Heart Failure

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600125852
Enrollment
Unknown
Registered
2026-06-01
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure

Interventions

Historical control group(Conventional treatment group):None
SGLT-2i group:None

Sponsors

Henan Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients meeting the diagnostic criteria for heart failure according to the Chinese Guidelines for the Diagnosis and Treatment of Heart Failure; 2. Age >= 18 years; 3. Patients in the SGLT-2i group with documented prescriptions of SGLT-2 inhibitors (such as dapagliflozin or empagliflozin) during hospitalization or outpatient care, and patients in the historical control group receiving standard heart failure therapy without SGLT-2 inhibitors before their widespread clinical use; 4. Complete baseline data and at least one follow-up record available.

Exclusion criteria

Exclusion criteria: 1. Severe comorbidities: Patients with end-stage renal disease (eGFR < 15 mL/min/1.73 m^2), type 1 diabetes, a history of diabetic ketoacidosis (DKA), or requiring dialysis; 2. Critical missing data: Lack of core evaluation indicators (such as missing baseline or follow-up echocardiography, NT-proBNP data); cases that cannot be matched due to major differences in follow-up frequency or examination methods between the historical control group data from previous medical records and the trial group; 3. Other interference: Clinical records indicate that patients participated in other interventional drug clinical trials during the follow-up period; 4. Pregnant or breastfeeding women: Special physiological periods indicated in relevant past records.

Design outcomes

Primary

MeasureTime frame
Number of recurrent heart failure hospitalizations;All-cause mortality;Heart failure hospitalization;

Secondary

MeasureTime frame
Change in NT-proBNP level;Incidence of adverse events;Change in estimated glomerular filtration rate;Change in left ventricular ejection fraction;

Countries

China

Contacts

Public ContactLi Bing

Henan Provincial People's Hospital

jzk_li@126.com+86 371 6558 1081

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026